Hallmark Capital Management Inc. Purchases 722 Shares of Amgen Inc. (AMGN)
Hallmark Capital Management Inc. raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,766 shares of the medical research company’s stock after acquiring an additional 722 shares during the period. Amgen makes up approximately 2.1% of Hallmark Capital Management Inc.’s holdings, making the stock its 17th biggest holding. Hallmark Capital Management Inc.’s holdings in Amgen were worth $15,977,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. TrimTabs Asset Management LLC grew its holdings in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC increased its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after purchasing an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares during the last quarter. American Beacon Advisors Inc. bought a new stake in Amgen in the first quarter worth $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new stake in Amgen during the first quarter valued at $121,000. 78.10% of the stock is currently owned by institutional investors and hedge funds.
AMGN has been the subject of several research reports. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group reissued a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Leerink Swann restated a “market perform” rating and set a $161.00 target price on shares of Amgen in a research report on Thursday, June 22nd. Finally, UBS AG set a $180.00 target price on shares of Amgen and gave the company a “hold” rating in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $188.41.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.4715% during midday trading on Wednesday, hitting $188.1128. The company’s stock had a trading volume of 826,338 shares. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10. The firm has a 50-day moving average of $179.85 and a 200 day moving average of $169.86. The firm has a market cap of $137.26 billion, a price-to-earnings ratio of 17.1339 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 EPS. On average, equities research analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were paid a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.46%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is 41.93%.
WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/04/hallmark-capital-management-inc-purchases-722-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.